These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1151 related items for PubMed ID: 10465102

  • 1. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 2. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 3. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS, Riley R, Hamilton BL, Paupe J, Perez D, Levy RB.
    Bone Marrow Transplant; 1994 Nov 01; 14(5):725-35. PubMed ID: 7889005
    [Abstract] [Full Text] [Related]

  • 4. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 5. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J, Gao L, Liu Y, Ren Y, Xie R, Fan H, Qian K.
    Transfusion; 2010 Feb 15; 50(2):407-17. PubMed ID: 19788510
    [Abstract] [Full Text] [Related]

  • 6. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
    Drobyski WR, Majewski D.
    Blood; 1997 Feb 01; 89(3):1100-9. PubMed ID: 9028343
    [Abstract] [Full Text] [Related]

  • 7. Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.
    Pillai A, Teo P, George T, Mukhopadhyay A, Dejbakhsh-Jones S, Strober S.
    Bone Marrow Transplant; 2007 Sep 01; 40(5):487-97. PubMed ID: 17603512
    [Abstract] [Full Text] [Related]

  • 8. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 01; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 9. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
    Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL.
    J Immunol; 1995 Jul 15; 155(2):585-93. PubMed ID: 7608537
    [Abstract] [Full Text] [Related]

  • 10. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 15; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 11. Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice.
    Brok HP, Vossen JM, Heidt PJ.
    Bone Marrow Transplant; 1997 Mar 15; 19(6):601-6. PubMed ID: 9085739
    [Abstract] [Full Text] [Related]

  • 12. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
    Davenport C, George T, Devora GA, Morris MA, Gordon BE, Kumar V, Bennett M.
    Biol Blood Marrow Transplant; 1997 Dec 15; 3(6):294-303. PubMed ID: 9502296
    [Abstract] [Full Text] [Related]

  • 13. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM, Gorechlad J, Larsen CP, Waller EK.
    Biol Blood Marrow Transplant; 2006 Dec 15; 12(12):1239-49. PubMed ID: 17162205
    [Abstract] [Full Text] [Related]

  • 14. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 15. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC, Friedman TM, Murphy GF, Korngold R.
    Biol Blood Marrow Transplant; 2004 Feb 15; 10(2):91-105. PubMed ID: 14750075
    [Abstract] [Full Text] [Related]

  • 16. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
    Jankowski RA, Ildstad ST.
    Hum Immunol; 1997 Feb 15; 52(2):155-61. PubMed ID: 9077564
    [Abstract] [Full Text] [Related]

  • 17. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH.
    J Immunol; 1986 Jan 15; 136(1):28-33. PubMed ID: 2933464
    [Abstract] [Full Text] [Related]

  • 18. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
    Perreault C, Allard A, Brochu S, Poupart C, Fontaine P, Bélanger R, Gyger M.
    Bone Marrow Transplant; 1990 Aug 15; 6(2):127-35. PubMed ID: 2145050
    [Abstract] [Full Text] [Related]

  • 19. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ.
    J Clin Invest; 1998 May 01; 101(9):1835-42. PubMed ID: 9576746
    [Abstract] [Full Text] [Related]

  • 20. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
    Xia G, Kovochich M, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2004 Nov 01; 10(11):748-60. PubMed ID: 15505606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.